Semaglutide and tirzepatide are different active ingredients with different mechanisms and FDA-approved brand indications. A clinician should determine whether either is appropriate for an individual patient.
Mechanism
Semaglutide is a GLP-1 receptor agonist. Tirzepatide activates both GIP and GLP-1 receptors. Those pharmacologic differences are one reason they should not be treated as interchangeable products.
Brand versus compounded forms
FDA-approved products containing these active ingredients exist, but compounded preparations are a separate regulatory category. FDA does not approve compounded drugs before marketing for safety, effectiveness or quality.
Cost and access
Cash-pay telehealth pricing can differ substantially. HealthRx currently advertises a lower starting monthly equivalent for compounded semaglutide than compounded tirzepatide.
What to ask your clinician
- Which medication, if any, is appropriate given my medical history?
- Am I considering an FDA-approved product or a compounded preparation?
- What side effects and warning signs should I know?
- What monitoring is needed?
- What is the expected total cost over the treatment period?
Decision principle
Do not choose solely because one drug is cheaper or because a provider advertises greater average weight loss. Individual appropriateness, safety, product status, access and follow-up all matter.
Sources & verification
We use primary sources for time-sensitive commercial and regulatory claims.
- FDA — Concerns with unapproved GLP-1 drugs used for weight loss
- FDA — Compounding and the FDA: Questions and Answers
- HealthRx — Pricing
Last reviewed: August 19, 2026